Bcl-2 Antagonists

Cat.No.	Product Name	Information	Product Use Citations
S1057	Obatoclax Mesylate (GX15-070)	Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis.	Nat Commun, 2025, 16(1):2416 bioRxiv, 2024, 10.1101/2023.01.18.524628 Emerg Microbes Infect, 2022, 1-29
S7100	WEHI-539	WEHI-539 has high affinity (IC50=1.1 nM) and selectivity for BCL-XL and potently kills cells by selectively antagonizing its prosurvival activity. This compound has more than a 400-fold higher affinity for BCL-XL versus other prosurvival BCL-2 family members.	bioRxiv, 2025, 2025.06.10.658786 Cell Rep Med, 2023, 4(11):101290 Leiden University The Netherlands, 2023,
S6709	Obatoclax (GX15-070)	Obatoclax (GX15-070) is an antagonist of Bcl-2 with an Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis.	Signal Transduct Target Ther, 2025, 10(1):161 Oncotarget, 2024, 15:614-633 Cells, 2023, 12(18)2247
S7126	Marinopyrrole A (Maritoclax)	Maritoclax (Marinopyrrole A) is a selective Mcl-1 antagonist that binds to Mcl-1, but not Bcl-XL, and targets it for proteasomal degradation. This compound disrupts the interaction between Bim and Mcl-1 with an IC50 of 10.1 μM.	Clin Cancer Res, 2023, 29(2):446-457 Cell Signal, 2022, S0898-6568(22)00041-9 Leukemia, 2019, 33(2):319-332
S7849	BDA-366	BDA-366 is a small-molecule Bcl2-BH4 domain antagonist and binds BH4 with high affinity and selectivity. It directly binds to Bcl2 with high binding affinity (Ki =3.3 ± 0.73 nM).	Biochem Pharmacol, 2025, S0006-2952(25)00712-9 BMC Cancer, 2023, 23(1):479